Neurofeedback for improving attention and reducing impulsivity in adults with ADHD
Effects of EEG- Microstate Neurofeedback on Attention and Impulsivity in Adult Attention-deficit/Hyperactivity Disorder (ADHD) and Neurotypical Controls
This study is testing whether a new brain training method can help adults with ADHD improve their attention and reduce impulsivity.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 18 Years to 50 Years |
| Sex | All |
| Sponsor | University Hospital, Geneva Academic / other |
| Locations | 1 site (Geneva) |
| Trial ID | NCT05582928 on ClinicalTrials.gov |
What this trial studies
This study investigates the effects of EEG microstate neurofeedback on attention and impulsivity in adults diagnosed with ADHD and healthy controls. Participants will engage in neurofeedback sessions aimed at manipulating EEG microstates, which are short-duration stable periods of brain activity. The study will assess neurophysiological, clinical, and behavioral outcomes to determine the efficacy of this novel approach. By exploring new biomarkers for ADHD, the research aims to enhance treatment options for individuals with this condition.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18-50 with a diagnosis of ADHD who are in general good health.
Not a fit: Patients with significant central nervous system disorders or current psychiatric comorbidities may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could provide a new therapeutic option for adults with ADHD, potentially improving their attention and reducing impulsivity.
How similar studies have performed: Previous studies have shown promise in using neurofeedback for ADHD, but this specific approach focusing on EEG microstates is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
ADHD POPULATION GROUP A subject will be eligible if all the following criteria apply: * Age: between 18-50 years * Gender: male and female * Health: general good health and normal or corrected-to-normal visual acuity * Patients clinically able to stop the following psychotropic medications for 48h: psychostimulants, benzodiazepines * Having provided written informed written consent A subject will not be eligible if any of the following criteria apply: * Past or current history of a clinically significant central nervous system disorder, including structural brain abnormalities; cerebrovascular disease; history of other neurological disease, epilepsy, stroke or head trauma (defined as loss of consciousness \> 5 min or requiring hospitalization) * Impaired vision (normal or corrected acuity below 20/40) * Medical illness (e.g., cardiovascular disease, renal failure, hepatic dysfunction) * Comorbidities with current psychiatric disorders (bipolar disorder, borderline personality disorder, major depressive disorder, anxiety disorder) including substance use disorder as defined by the DIGS. HEALTHY POPULATION GROUP A subject will be eligible if all of the following criteria apply: * Age: between 18-50 years * Gender: male and female * Health: general good health and normal or corrected-to-normal visual acuity * Having provided written informed written consent A subject will not be eligible if any of the following criteria apply: * Past or current history of ADHD * Past or current history of main psychiatric disorders (bipolar disorder, borderline personality disorder, major depressive disorder, anxiety disorder), including substance use disorder as defined by the DIGS. * Past or current history of a clinically significant central nervous system disorder, including structural brain abnormalities; cerebrovascular disease; history of other neurological disease, including epilepsy, stroke or head trauma (defined as loss of consciousness \> 5 min or requiring hospitalization) * Impaired vision (normal or corrected acuity below 20/40) * Medical illness (e.g., cardiovascular disease, renal failure, hepatic dysfunction)
Where this trial is running
Geneva
- TRE Unit (Trouble de la Régulation Emotionnelle) Department of psychiatry, HUG — Geneva, Switzerland (Recruiting)
Study contacts
- Principal investigator: Nader Perroud, Professor — University Hospital, Geneva
- Study coordinator: Nader Perroud, Professor
- Email: nader.perroud@hcuge.ch
- Phone: +41 22 305 45 11
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.